| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$315 |
Application for quotation of securities - BRN
|
28 Feb 2025 9:57AM |
$0.258 |
$0.140 |
fallen by
45.63%
|
|
| Acorn Capital Investment Fund Limited (ACQ) ORDINARY FULLY PAID |
Financials |
$87 |
Update - Dividend/Distribution - ACQ
|
28 Feb 2025 9:56AM |
$0.800 |
$0.970 |
risen by
21.25%
|
|
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Results Presentation
|
28 Feb 2025 9:55AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$360 |
FY24 Results Investor Presentation
|
28 Feb 2025 9:55AM |
$1.170 |
$1.230 |
risen by
5.13%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Loan book growth of 13% driven by strong business lending.
- Foreign exchange revenues increased by 68% due to customer inflows.
- Digital channels and partnerships saw a 27% year-on-year growth.
- Underlying NPAT increased by 7%, with net profit before tax up 5%.
- The company maintained a dividend per share of 10.0 cents.
- Capital adequacy remains healthy, supporting growth opportunities.
- Kina Securities recognized for innovation in the Pacific banking sector.
- Community programs supported 14 small-scale projects in Papua New Guinea.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aeris Resources Limited (AIS) ORDINARY FULLY PAID |
Materials |
$593 |
INVESTOR PRESENTATION
|
28 Feb 2025 9:55AM |
$0.165 |
$0.495 |
risen by
200%
|
|
AIS - Price-sensitive ASX Announcement
Full Release
Key Points
- Aeris Resources Limited is an Australian mid-tier base and precious metals producer.
- The company has two producing operations with a FY25 production guidance of 40-48kt copper equivalent.
- It has three development projects poised for growth and exploration.
- Strategically located assets are aligned with a focus on copper production.
- Tritton is identified as a cornerstone asset with significant resource potential.
- Strong operating cash flow is funding further growth and development initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Results Announcement
|
28 Feb 2025 9:55AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| The Star Entertainment Group Limited (SGR) ORDINARY FULLY PAID |
Consumer Discretionary |
$896 |
Pause in Trading
|
28 Feb 2025 9:54AM |
$0.130 |
$0.135 |
risen by
3.85%
|
|
SGR - Price-sensitive ASX Announcement
Full Release
Key Points
- The Star Entertainment Group Limited has paused trading in its securities.
- The trading halt is pending a further announcement.
- The halt is in compliance with ASX Listings requirements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Careteq Limited (CTQ) ORDINARY FULLY PAID |
Health Care |
$3 |
1HFY25 Appendix 4D and Half Year Report
|
28 Feb 2025 9:54AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
CTQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Careteq Limited divested its Sofihub business for $0.58 million.
- Acquired remaining 45% of Embedded Health Solutions for $2.4 million.
- Revenue increased by 15.5% to $4.0 million in 1H FY25.
- EBITDA from continuing operations improved to $0.24 million.
- Net loss reduced by 89.8% to $150,152.
- Partnerships with MedicAlert and GP networks to enhance medication safety.
- The company expects continued revenue growth and positive EBITDA for FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$31 |
Appendix 4E - Preliminary Final Report
|
28 Feb 2025 9:53AM |
$0.030 |
$0.084 |
risen by
180%
|
|
HCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue declined 6% to $5.6 million.
- Net loss reduced by 98% to $84,000.
- Launched new products SKNPRO Collagen and PROBIO-30.
- Recovered $1 million from receivables.
- Secured forward orders worth $163,000 from Nano Malaysia.
- Ovine Collagen segment experienced a 50.7% sales decline but has potential new applications.
- Company is in discussions for a new manufacturing facility in collaboration with governments in Australia and Malaysia.
- Proceeds from new converting notes will support ongoing initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$31 |
Proposed issue of securities - HCT
|
28 Feb 2025 9:53AM |
$0.030 |
$0.084 |
risen by
180%
|
|
| Altech Batteries Limited (ATC) ORDINARY FULLY PAID |
Materials |
$67 |
Acquisition of Additional Investments CERENERGY & Silumina
|
28 Feb 2025 9:53AM |
$0.045 |
$0.025 |
fallen by
44.44%
|
|
ATC - Price-sensitive ASX Announcement
Full Release
Key Points
- Altech to acquire additional 18.75% stake in CERENERGY® Project and additional 25% stake in Silumina AnodesTM Project.
- Post-acquisition, Altech will hold 100% ownership of the Silumina AnodesTM Project and 75% of the CERENERGY® Project.
- The transaction includes the issuance of approximately 532 million shares to AAM.
- The acquisitions are valued at approximately A$23.3 million.
- AAM will remain aligned with Altech's success through its 21% equity stake post-acquisition.
- The transaction is subject to shareholder approvals and necessary regulatory conditions.
- The acquisition aims to improve operational efficiency and consolidate project ownership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$9 |
Cancel - Proposed issue of securities - BIT
|
28 Feb 2025 9:53AM |
$0.009 |
$0.004 |
fallen by
61.11%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$360 |
FY24 Results ASX Announcement
|
28 Feb 2025 9:53AM |
$1.170 |
$1.230 |
risen by
5.13%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Kina Securities Limited reported FY24 NPAT growth of 7% to PGK111.9 million.
- Net interest income increased by 15% year-on-year.
- Loan book grew by 13% year-on-year.
- Non-interest income grew by 33%, driven by FX income and digital channels.
- Total operating costs increased by 31% year-on-year.
- Final dividend declared at AUD 6.0 cents per share for 2H24.
- Cost to income ratio was 58.6% for the year.
- Capital adequacy maintained at 18.4%, supporting growth.
- KSL aims for further earnings growth in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$315 |
Application for quotation of securities - BRN
|
28 Feb 2025 9:53AM |
$0.258 |
$0.140 |
fallen by
45.63%
|
|
| Hudson Investment Group Limited (HGL) ORDINARY FULLY PAID |
Real Estate |
- |
Appendix 4E
|
28 Feb 2025 9:52AM |
$0.175 |
$0.175 |
fallen by
0%
|
|
HGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated net loss after tax was $1.37 million for the year ended December 31, 2024.
- Revenue from ordinary activities rose by 1.2% to $1.498 million.
- Company does not recommend any dividends for the year.
- Engaged Knight Frank Central Coast for expressions of interest on property sales.
- Focus on optimizing current property portfolio for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Parkd Ltd (PKD) ORDINARY FULLY PAID |
Industrials |
$4 |
Appendix 4D and Interim Financial Report
|
28 Feb 2025 9:52AM |
$0.050 |
$0.031 |
fallen by
38%
|
|
PKD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 508% to $6,179,314.
- Loss for the period was $82,252, down from $119,778.
- Key projects included Audi Centre Myaree and John Hughes Forward Street car park.
- Licensing agreement signed with Fielders for PARKD's intellectual property.
- Net operating cash inflow improved to $175,244.
- Total cash and cash equivalents were $761,623 as of December 31, 2024.
- Directors believe PARKD can continue as a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$122 |
ASX waiver from requirement to lodge an Appendix 4E
|
28 Feb 2025 9:51AM |
$11.200 |
$7.400 |
fallen by
33.93%
|
|
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$9 |
Proposed issue of securities - BIT
|
28 Feb 2025 9:51AM |
$0.009 |
$0.004 |
fallen by
61.11%
|
|
| Panther Metals Ltd (PNT) ORDINARY FULLY PAID |
Materials |
$4 |
Trading Halt
|
28 Feb 2025 9:51AM |
$0.015 |
$0.009 |
fallen by
40%
|
|
PNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Panther Metals Ltd requested a trading halt.
- The halt is pending a capital raising announcement.
- The trading halt will end by March 4, 2025, or when the announcement is released.
- Company Secretary Damon Cox issued the request to ASX Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$90 |
BXN H1 FY25 Results Presentation
|
28 Feb 2025 9:51AM |
$0.034 |
$0.040 |
risen by
17.65%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue growth of 171% to $12.6m for H1 FY25.
- Positive operating cash flow of $3.0m.
- Positive EBITDA of $3.7m.
- First company licensed by TGA in Australia to manufacture Psilocybin & MDMA products.
- Executed multiple supply agreements expected to generate $50m in sales across 2 years.
- Minimum revenue guidance of $25.0m for FY25.
- Strong performance from cannabis-focused SKUs.
- Expansion of production capabilities underway.
- Significant cash on hand of $2.7m at the end of H1 FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Mid-year Market Update
|
28 Feb 2025 9:51AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited focuses on technology innovations improving lives.
- The company has increased sales contracts and reduced operational costs.
- It aims for over 10% growth in international revenues.
- The company is converting its sales pipeline to annual recurring revenues.
- Hydrix has a strong portfolio of innovative products in cardiovascular disease management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$32 |
H1 FY25 Results Presentation
|
28 Feb 2025 9:50AM |
$0.020 |
$0.040 |
risen by
100%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomo develops innovative rapid tests for point-of-care testing.
- Significant revenue growth of more than 80% in FY24.
- HIV self-testing is projected to grow to US$531m by 2026.
- Atomo is the only registered HIV self-test approved for sale in Australia.
- Active syphilis test development is supported by a $2.44m government grant.
- Atomo's products are registered in more than 30 countries.
- The company has a strong focus on user-centric design and usability.
- Expansion into new markets in Europe and South America is planned.
- Ongoing investment in research and development is aimed at enhancing product offerings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$9 |
Renounceable Rights Issue
|
28 Feb 2025 9:50AM |
$0.009 |
$0.004 |
fallen by
61.11%
|
|
BIT - Price-sensitive ASX Announcement
Full Release
Key Points
- 1 for 1 Renounceable Rights Issue to raise up to $2.7 million
- Priced at 0.3 cents per share
- Discount of 66% to the last price of 0.9 cents
- Shareholders can trade their rights starting from 5 March 2025
- Directors intend to participate for their full entitlements
- Funds to support antiviral programs including BIT225
- Conduct a small animal study of Hepatitis B virus compound
- Maintain existing patents and file new ones
- Rights issue partially underwritten for $750,000 by Mahe Capital
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Motorcycle Holdings Limited (MTO) ORDINARY FULLY PAID |
Consumer Discretionary |
$188 |
Appendix 3Z - Martin Ward
|
28 Feb 2025 9:49AM |
$1.980 |
$2.540 |
risen by
28.28%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$5 |
Trading Update and Growth Outlook
|
28 Feb 2025 9:49AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix recorded consecutive profitable quarters with improved margins and lower operating costs.
- $7.4 million in contract sales orders, a 37% improvement from the previous comparable period.
- Potential future project revenues of $40 million from 15 active clients.
- Cash operating loss significantly improved to $0.39 million from $2.09 million in the prior year.
- Hydrix Medical is expanding sales opportunities in the cardiac and medtech sectors.
- Gyder Surgical received FDA clearance, triggering a $0.36 million valuation increase for Hydrix Ventures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
